Phase 2 Readouts
Phase 2 trials test drug efficacy in 100-300 patients with the target condition. Positive Phase 2 data validates the drug mechanism and sets the stage for pivotal Phase 3 trials.
158 phase 2 readouts tracked, next on Sep 1, 2026. Event dates and source records are shown with their available source context.
Phase 2 Readout: neo100
NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)
Phase 2 Readout: tyra-300
Tyra Biosciences, Inc. (TYRA)
Phase 2 Readout: relutrigine
Praxis Precision Medicines, Inc. (PRAX)
Phase 2 Readout: rad101
Radiopharm Theranostics Limited (RADX)
Phase 2 Readout: fid-007
Fulgent Genetics Inc. (FLGT)
Phase 2 Readout: sion-719
Sionna Therapeutics, Inc. (SION)
Phase 2 Readout: avtx-009
Avalo Therapeutics, Inc. (AVTX)
Phase 2 Readout: elsunersen
Praxis Precision Medicines, Inc. (PRAX)
Phase 2 Readout: obexelimab
Zenas BioPharma, Inc. (ZBIO)
Phase 2 Readout: volixibat
Mirum Pharmaceuticals, Inc. (MIRM)
Phase 2 Readout: apg777
Apogee Therapeutics, Inc. (APGE)
Phase 2 Readout: rese-cel
Cabaletta Bio, Inc. (CABA)
Phase 2 Readout: ngc-cap
Processa Pharmaceuticals, Inc. (PCSA)
Phase 2 Readout: reqorsa
Genprex, Inc. (GNPX)
Phase 2 Readout: rademikibart
Connect Biopharma Holdings Ltd (CNTB)
Phase 2 Readout: zumilokibart
Apogee Therapeutics, Inc. (APGE)
Phase 2 Readout: bx004
BiomX Inc. (PHGE)
Phase 2 Readout: 150
4D Molecular Therapeutics, Inc. (FDMT)
Phase 2 Readout: aficamten
CYTOKINETICS INC (CYTK)
Phase 2 Readout: Major Depressive Disorder
SPRUCE BIOSCIENCES, INC. (SPRB)
Phase 2 Readout: signal-aa part b
Q32 Bio Inc. (QTTB)
Phase 2 Readout: bempikibart
Q32 Bio Inc. (QTTB)
Phase 2 Readout: kyv-101
Kyverna Therapeutics, Inc. (KYTX)
Phase 2 Readout: bezisterim
BIOVIE INC. (BIVI)
Phase 2 Readout: pipeline candidate
Entrada Therapeutics, Inc. (TRDA)
Phase 2 Readout: bempikibart
Q32 Bio Inc. (QTTB)
Phase 2 Readout: ml-007c-ma
MapLight Therapeutics, Inc. (MPLT)
Phase 2 Readout: elpis ii
Longeveron Inc. (LGVN)
Phase 2 Readout: laromestrocel
Longeveron Inc. (LGVN)
Phase 2 Readout: neo100
NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)
Phase 2 Readout: rademikibart
Connect Biopharma Holdings Ltd (CNTB)
Phase 2 Readout: ost-her2
OS Therapies Inc (OSTX)
Phase 2 Readout: esk-001
ALUMIS INC. (ALMS)
Phase 2 Readout: nxc-201
Immix Biopharma, Inc. (IMMX)
Phase 2 Readout: sl-325
Shattuck Labs, Inc. (STTK)
Phase 2 Readout: pali-2108
PALISADE BIO, INC. (PALI)
Phase 2 Readout: abcl635
AbCellera Biologics Inc. (ABCL)
Phase 2 Readout: bezisterim
BIOVIE INC. (BIVI)
Phase 2 Readout: nimacimab
Skye Bioscience, Inc. (SKYE)
Phase 2 Readout: halneuron
Dogwood Therapeutics, Inc. (DWTX)
Phase 2 Readout: divesiran
Silence Therapeutics Plc (SLN)
Phase 2 Readout: intranasal foralumab
Tiziana Life Sciences Ltd (TLSA)
Phase 2 Readout: nexicart-2
JOHNSON & JOHNSON (JNJ)
Phase 2 Readout: namodenoson
Can-Fite BioPharma Ltd. (CANF)
Phase 2 Readout: piclidenoson
Can-Fite BioPharma Ltd. (CANF)
Phase 2 Readout: ep-104gi
EUPRAXIA PHARMACEUTICALS INC. (EPRX)
Phase 2 Readout: revita
Fractyl Health Inc. (GUTS)
Phase 2 Readout: gt-02287
Gain Therapeutics, Inc. (GANX)
Phase 2 Readout: evorpacept
ALX ONCOLOGY HOLDINGS INC (ALXO)
Phase 2 Readout: pipeline candidate
MapLight Therapeutics, Inc. (MPLT)
Phase 2 Readout: RA
Spyre Therapeutics, Inc. (SYRE)
Phase 2 Readout: envudeucitinib
ALUMIS INC. (ALMS)
Phase 2 Readout: ml-007c-ma
MapLight Therapeutics, Inc. (MPLT)
Phase 2 Readout: tafenoquine
60 DEGREES PHARMACEUTICALS, INC. (SXTP)
Phase 2 Readout: com701
COMPUGEN LTD (CGEN)
Phase 2 Readout: ax-0810
ProQR Therapeutics N.V. (PRQR)
Phase 2 Readout: silevertinib
Black Diamond Therapeutics, Inc. (BDTX)
Phase 2 Readout: pelareorep
ONCOLYTICS BIOTECH INC (ONCY)
Phase 2 Readout: olvi-vec
GENELUX Corp (GNLX)
Phase 2 Readout: breast cancer vaccine
Anixa Biosciences Inc (ANIX)
Phase 2 Readout: agent-797
MiNK Therapeutics, Inc. (INKT)
Phase 2 Readout: type 2 diabetes
Biomea Fusion, Inc. (BMEA)
Phase 2 Readout: halneuron
Dogwood Therapeutics, Inc. (DWTX)
Phase 2 Readout: img-007
ImageneBio, Inc. (IMA)
Phase 2 Readout: adi-212
Adicet Bio, Inc. (ACET)
Phase 2 Readout: neflamapimod
CervoMed Inc. (CRVO)
Phase 2 Readout: pevifoscorvir
Aligos Therapeutics, Inc. (ALGS)
Phase 2 Readout: enobosarm
VERU INC. (VERU)
Phase 2 Readout: tti-101
Tvardi Therapeutics, Inc. (TVRD)
Phase 2 Readout: lti-03
Rein Therapeutics, Inc. (RNTX)
Phase 2 Readout: calma
IGC Pharma, Inc. (IGC)
Phase 2 Readout: vtp-300
Barinthus Biotherapeutics plc. (BRNS)
Phase 2 Readout: skinject
Medicus Pharma Ltd. (MDCX)
Phase 2 Readout: remlifansirin
ACADIA PHARMACEUTICALS INC (ACAD)
Phase 2 Readout: remlifanserin
ACADIA PHARMACEUTICALS INC (ACAD)
Phase 2 Readout: hidradenitis suppurativa (HS)
AbbVie Inc. (ABBV)
Phase 2 Readout: volixibat
Mirum Pharmaceuticals, Inc. (MIRM)
Phase 2 Readout: pcrx-201
Pacira BioSciences, Inc. (PCRX)
Phase 2 Readout: kt-621
Kymera Therapeutics, Inc. (KYMR)
Phase 2 Readout: aleniglipron
Structure Therapeutics Inc. (GPCR)
Phase 2 Readout: xmab942
Xencor Inc (XNCR)
Phase 2 Readout: bp1.15205
Harmony Biosciences Holdings, Inc. (HRMY)
Phase 2 Readout: voquezna
Phathom Pharmaceuticals, Inc. (PHAT)
Phase 2 Readout: oncology
BioNTech SE (BNTX)
Phase 2 Readout: zumilokibart
Apogee Therapeutics, Inc. (APGE)
Phase 2 Readout: apg777
Apogee Therapeutics, Inc. (APGE)
Phase 2 Readout: dabogratinib
Tyra Biosciences, Inc. (TYRA)
Phase 2 Readout: dt402
Definium Therapeutics Inc. (DFTX)
Phase 2 Readout: azenosertib
Zentalis Pharmaceuticals, Inc. (ZNTL)
Phase 2 Readout: rese-cel
Cabaletta Bio, Inc. (CABA)
Phase 2 Readout: spy072
Spyre Therapeutics, Inc. (SYRE)
Phase 2 Readout: spy002
Spyre Therapeutics, Inc. (SYRE)
Phase 2 Readout: kpl-387
Kiniksa Pharmaceuticals International, plc (KNSA)
Phase 2 Readout: sevasemten
Edgewise Therapeutics, Inc. (EWTX)
Phase 2 Readout: envudeucitinib
ALUMIS INC. (ALMS)
Phase 2 Readout: mze829
Maze Therapeutics, Inc. (MAZE)
Phase 2 Readout: orka-001
Oruka Therapeutics, Inc. (ORKA)
Phase 2 Readout: bpl-003
Atai Beckley N.V. (ATAI)
Phase 2 Readout: haduvio
Trevi Therapeutics, Inc. (TRVI)
Phase 2 Readout: obexelimab
Zenas BioPharma, Inc. (ZBIO)
Phase 2 Readout: vir-5818
Vir Biotechnology, Inc. (VIR)
Phase 2 Readout: mrt-6160
Monte Rosa Therapeutics, Inc. (GLUE)
Phase 2 Readout: inbrx-106
Inhibrx Biosciences, Inc. (INBX)
Phase 2 Readout: bge-102
BioAge Labs, Inc. (BIOA)
Phase 2 Readout: Obesity
BioAge Labs, Inc. (BIOA)
Phase 2 Readout: jade101
Jade Biosciences, Inc. (JBIO)
Phase 2 Readout: sls009
SELLAS Life Sciences Group, Inc. (SLS)
Phase 2 Readout: aav-haqp1
MeiraGTx Holdings plc (MGTX)
Phase 2 Readout: pemvidutide
Altimmune, Inc. (ALT)
Phase 2 Readout: et-700
Eton Pharmaceuticals, Inc. (ETON)
Phase 2 Readout: nereus
Vanda Pharmaceuticals Inc. (VNDA)
Phase 2 Readout: abi-6250
ASSEMBLY BIOSCIENCES, INC. (ASMB)
Phase 2 Readout: tibulizumab
Zura Bio Ltd (ZURA)
Phase 2 Readout: ep-104gi
EUPRAXIA PHARMACEUTICALS INC. (EPRX)
Phase 2 Readout: abs-201
Absci Corporation (ABSI)
Phase 2 Readout: pipeline candidate
Absci Corporation (ABSI)
Phase 2 Readout: fb102
Forte Biosciences, Inc. (FBRX)
Phase 2 Readout: atebimetinib
Immuneering Corp (IMRX)
Phase 2 Readout: budoprutug
Climb Bio, Inc. (CLYM)
Phase 2 Readout: avtx-009
Avalo Therapeutics, Inc. (AVTX)
Phase 2 Readout: pipeline candidate
AC Immune SA (ACIU)
Phase 2 Readout: pipeline candidate
Opus Genetics, Inc. (IRD)
Phase 2 Readout: tagmokitug/casdozokitug
Coherus Oncology, Inc. (CHRS)
Phase 2 Readout: neo100
NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)
Phase 2 Readout: descartes-08
Cartesian Therapeutics, Inc. (RNAC)
Phase 2 Readout: tvb-3567
Sagimet Biosciences Inc. (SGMT)
Phase 2 Readout: Liver Treatment
Sagimet Biosciences Inc. (SGMT)
Phase 2 Readout: tnx-4800
Tonix Pharmaceuticals Holding Corp. (TNXP)
Phase 2 Readout: sat-3247
Satellos Bioscience Inc. (MSLE)
Phase 2 Readout: intranasal foralumab
Tiziana Life Sciences Ltd (TLSA)
Phase 2 Readout: sabirnetug
Acumen Pharmaceuticals, Inc. (ABOS)
Phase 2 Readout: laromestrocel
Longeveron Inc. (LGVN)
Phase 2 Readout: al001
Alzamend Neuro, Inc. (ALZN)
Phase 2 Readout: lam-001
Quince Therapeutics, Inc. (QNCX)
Phase 2 Readout: reqorsa
Genprex, Inc. (GNPX)
Phase 2 Readout: ampligen
AIM ImmunoTech Inc. (AIM)
Phase 2 Readout: qrx003
Quoin Pharmaceuticals, Ltd. (QNRX)
Phase 2 Readout: lasme-cel
Cellectis S.A. (CLLS)
Phase 2 Readout: imvt-1402
Immunovant, Inc. (IMVT)
Phase 2 Readout: imvt-1402
Roivant Sciences Ltd. (ROIV)
Phase 2 Readout: vis-101
NovaBridge Biosciences (NBP)
Phase 2 Readout: alpha dart
Alpha Tau Medical Ltd. (DRTS)
Phase 2 Readout: revita
Fractyl Health Inc. (GUTS)
Phase 2 Readout: pipeline candidate
Denali Therapeutics Inc. (DNLI)
Phase 2 Readout: cr-001
CRESCENT BIOPHARMA, INC. (CBIO)
Phase 2 Readout: volixibat
Mirum Pharmaceuticals, Inc. (MIRM)
Phase 2 Readout: zeleciment basivarsen
Dyne Therapeutics, Inc. (DYN)
Phase 2 Readout: com701
COMPUGEN LTD (CGEN)
Phase 2 Readout: z-basivarsen
Dyne Therapeutics, Inc. (DYN)
Phase 2 Readout: enobosarm + semaglutide
VERU INC. (VERU)
Phase 2 Readout: enobosarm
VERU INC. (VERU)
Phase 2 Readout: efzofitimod
aTYR PHARMA INC (ATYR)
Phase 2 Readout: alstars
Coya Therapeutics, Inc. (COYA)
Phase 2 Readout: maia
COMPUGEN LTD (CGEN)
Phase 2 Readout: rap-219
Rapport Therapeutics, Inc. (RAPP)
Phase 2 Readout: kt-621
Kymera Therapeutics, Inc. (KYMR)
Phase 2 Readout: reqorsa
Genprex, Inc. (GNPX)
Phase 2 Readout: rese-cel
Cabaletta Bio, Inc. (CABA)
Frequently asked questions
What does a Phase 2 readout show?
Phase 2 trials (typically 100-300 patients) provide the first efficacy and dose-finding signals in the target patient population.
Why do investors watch Phase 2 data?
Positive Phase 2 results validate a drug's mechanism and de-risk the move into pivotal Phase 3 trials, often re-rating early-stage biotech valuations.
Are Phase 2 readout dates exact?
They are estimated windows based on enrollment and completion timelines; BioSniper updates them as company guidance changes.
Learn more
Biotech Clinical Trial Phases Explained: What Investors Need to Know
A comprehensive guide to Phase 1, Phase 2, and Phase 3 clinical trials — what happens at each stage, success rates, and what results mean for biotech stocks.
Phase 3 Trial Endpoints Explained: P-Values, Hazard Ratios, and What Investors Need to Know
Demystify clinical trial statistics for biotech investing. Learn how to interpret p-values, hazard ratios, confidence intervals, and primary endpoints in Phase 3 trials.
FDA Breakthrough Therapy Designation: What It Means for Drug Development and Investors
Understand what FDA Breakthrough Therapy Designation is, how it accelerates drug development, approval success rates, and investment implications for biotech stocks.
Key terms
From catalyst type to protocol condition
Decide when this event type should matter
Set the timing, confidence, company, drug, trial, and financing conditions that must hold before this catalyst changes a decision.